Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03966118
Title Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma (AIO-STO-0218)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors P. C. Thuss-Patience
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Avelumab + Paclitaxel + Ramucirumab

Age Groups: senior | adult
Covered Countries DEU


No variant requirements are available.